Tamoxifen: A review of drug development for use in breast cancer and ocular adverse reactions

1 May 2003
Volume 04, Issue 2

The development of tamoxifen - from the early laboratory studies to the present-day use.


The ideal treatment in any type of cancer is curative. Unfortunately, this is not yet an achievable goal with breast cancer. Therefore, the available treatment should aim to prolong life without diminishing the quality of life. Tamoxifen has been the most widely used endocrine therapy in the past 30 years for the treatment of metastatic breast cancer (Buzdar 2001). The incidence of side effects is low but ocular adverse reactions (OARs) have been regularly reported for this drug. The aim of this review is to look briefly at the development of tamoxifen from the early laboratory studies to the present-day use in treatment of breast cancer. The OARs associated with tamoxifen will be discussed and related to the clinical findings in practice. New drugs in development for the endocrine treatment of the disease will be briefly compared to tamoxifen. 

Sign in to continue

Forgotten password?

Not already a member of The College?

Start enjoying the benefits of College membership today. Take a look at what the College can offer you and view our membership categories and rates.

Related further reading

We believe that vaccine uptake will be maximised where staff are supported to make their own decisions, having been provided with clear, evidence-based information on the benefit and value of vaccinations.

Following the announcement by the Secretary for Health that the isolation period for people who test positive for COVID-19 will be cut to five full days in England, NHSE has confirmed this will apply in primary care settings.

UKHSA confirms that changes to the self-isolation period following Covid exposure applies to healthcare workers